Abstract: A board connection structure including a wiring board having a contact point section provided at one end portion and opposed to a switch button, and a holding member to which the wiring board is attached with flat surfaces of the contact point section and the connection section on the same surface intersecting with each other by the folding of the wiring board.

Abstract: An electronic device of the present invention has a battery storage structure with a battery pack inserted into a battery storage section provided in a device case, a battery electrode provided on a side surface of the battery pack that comes in contact with a connection electrode provided within the battery storage section and the battery storage section is openably/closably covered by a battery cover. This electronic device includes a locking member which engageably locks the battery pack into the battery storage section by sliding the battery pack into place, and a guide pressing section provided on the battery cover which presses the battery pack towards the connection electrode once inserted between inner surface parts positioned on opposite sides of the connection electrode of the battery storage section and the battery pack opposing side with the battery cover covering the battery storage section where the battery pack is stored.

Abstract: [Problem] The purpose of the present invention is to stably supply high-quality and highly uniform Wisteria floribunda agglutinin (WFA) that recognizes biologically important sugar-chain markers, to elucidate the sugar-chain recognition activity in detail, and to furthermore increase the specificity of the sugar-chain recognition activity. [Solution] The present invention involves the development of a technique for cloning genes for coding Wisteria floribunda agglutinin (WFA) and producing recombinant WFA having the same sugar-chain recognition activity as natural WFA from transformed bacteria. Natural WFA is reduced to thereby manufacture a reduced WFA monomer for specifically recognizing terminal GalNAc residue. A recombinant monomer WFA for recognizing LDN (GalNAc?1, 4GlcNAc) sugar chain, which is important as a diagnostic marker among sugar chains having a terminal GalNAc residue, is manufactured by introducing cysteine mutation to recombinant WFA or by C-terminal-side amino acid deletion.

Abstract: The present invention provides: genetically modified yeasts such as mutant yeasts having an ability to produce N-linked sugar chains of Man5GlcNAc2 and a decreased ability to produce O-linked sugar chains, mutant yeasts having an ability to produce N-linked sugar chains of Man5GlcNAc2 and further having an ability to produce N-linked sugar chains of GlcNAc1Man5GlcNAc2, and mutant yeasts having an increased ability to produce and secrete proteins and an ability to produce N-linked sugar chains of Man5GlcNAc2; and a method for producing glycoproteins using them.

Abstract: The present invention provides a novel endo-?-N-acetylglucosaminidase (Endo-Om) using a transformant produced by cloning an endo-?-N-acetylglucosaminidase (Endo-Om) gene originated from a methylotrophic yeast Ogataea minuta IFO10746 strain. The Endo-Om according to the present invention has a specific activity 13-fold higher than that of known Endo-M and a Vmax value 55-fold higher than that of the known Endo-M, and is useful for the analysis of the structures of sugar chains, including complex type sugar chains, in glycoproteins and the modification of the sugar chains.

Abstract: The present invention provides a means to ensure a further increase in the therapeutic effects provided by enzyme replacement therapy against lysosomal disease. The present invention is directed to a recombinant human saposin B protein containing phosphorylated carbohydrate chains, a lysosomal enzyme activator comprising such a recombinant protein, and a pharmaceutical composition for treatment of lysosomal disease, which comprises such a recombinant protein and a lysosomal enzyme, etc.

Abstract: [Problem to be Solved] The importance of sugar chains having ?2,3- or ?2,6-linked sialic acid at their non-reducing ends is known. Industrial production has been demanded for these sugar chain compounds. Particularly, the production of glycoprotein drugs or the like inevitably requires producing in quantity sugar chains having homogeneous structures by controlling the linking pattern (?2,6-linkage or ?2,3-linkage) of sialic acid. Particularly, a triantennary or tetraantennary N-type complex sugar chain having sialic acid at each of all non-reducing ends is generally considered difficult to chemically synthesize. There has been no report disclosing that such a sugar chain was chemically synthesized. Furthermore, these sugar chains are also difficult to efficiently prepare enzymatically.

Abstract: An electronic device of the present invention has a flat-type device case whose front surface is provided with an imaging section and which is covered by a foldable cover, and includes an open/close detecting section which detects an open/close angle of the cover when the cover covers the device case, and outputs a detection signal for causing the imaging section to perform imaging.

Abstract: An electronic device of the present invention has a battery storage structure with a battery pack inserted into a battery storage section provided in a device case, a battery electrode provided on a side surface of the battery pack that comes in contact with a connection electrode provided within the battery storage section and the battery storage section is openably/closably covered by a battery cover. This electronic device includes a locking member which engageably locks the battery pack into the battery storage section by sliding the battery pack into place, and a guide pressing section provided on the battery cover which presses the battery pack towards the connection electrode once inserted between inner surface parts positioned on opposite sides of the connection electrode of the battery storage section and the battery pack opposing side with the battery cover covering the battery storage section where the battery pack is stored.

Abstract: The present invention provides: genetically modified yeasts such as mutant yeasts having an ability to produce N-linked sugar chains of Man5GlcNAc2 and a decreased ability to produce O-linked sugar chains, mutant yeasts having an ability to produce N-linked sugar chains of Man5GlcNAc2 and further having an ability to produce N-linked sugar chains of GlcNAc1Man5GlcNAc2, and mutant yeasts having an increased ability to produce and secrete proteins and an ability to produce N-linked sugar chains of Man5GlcNAc2; and a method for producing glycoproteins using them.

Abstract: This invention provides a means for high-level secretory production of a protein, and, in particular, a protein having a complicated structure such as an antibody, in a host cell such as a yeast cell. This invention provides a method for high-level secretory production of a foreign protein with the use of a transformed host cell having one or more types of chaperone protein genes and via suppression of O sugar chain inherent to a host cell such as a yeast cell.

Abstract: This invention provides a means for enabling high-level secretory production of proteins, in particular proteins having complicated structures such as antibodies, in host cells such as yeast cells. The invention also provides transformed yeast cells having the activated HAC1 gene and the RRBP1 gene and a method for enabling high-level secretory production of foreign proteins using such transformed host cells by inhibiting O-sugar chain formation indigenous to host cells such as yeast cells.

Abstract: This invention is to provide a process for producing a glycoprotein comprising a mammalian type sugar chain, characterized in that the process comprises introducing an ?-1,2-mannosidase gene into a methylotrophic yeast having a mutation of a sugar chain biosynthesizing enzyme gene, so that the ?-1,2-mannosidase gene is expressed under the control of a potent promoter in the yeast; culturing in a medium the methylotrophic yeast cells with a heterologous gene transferred thereinto; and obtaining the glycoprotein comprising a mammalian type sugar chain from the culture. Using the newly created methylotrophic yeast having a sugar chain mutation, a neutral sugar chain identical with a high mannose type sugar chain produced by mammalian cells such as human cells, or a glycoprotein comprising such a neutral sugar chain, can be produced in a large amount at a high purity.

Abstract: This invention provides a means for high-level secretory production of a protein, and, in particular, a protein having a complicated structure such as an antibody, in a host cell such as a yeast cell. This invention provides a method for high-level secretory production of a foreign protein with the use of a transformed host cell having one or more types of chaperone protein genes and via suppression of O sugar chain inherent to a host cell such as a yeast cell.

Abstract: An electronic handheld device includes: a case that is formed in a longitudinal boxed shape; a first operation key that is provided on a front face of the case at a position that is located at an approximate center of the front face; and a first concave portion that is formed on a back face of the case at a first position opposite the position of the first operation key, the first concave portion being arched toward a top end of the case.

Abstract: A method for breeding yeast having thermotolerance or recovering growth activity and a method for breeding yeast which produces beta-glucan efficiently as well as an yeast obtained by such methods for breeding are presented by a method for breeding yeast having thermotolerance or recovering growth activity including a step for controlling proofreading function of DNA polymerase in a loss-of-function mutant of yeast (for example, a step for including mutant pol3 gene or mutant cdc6? gene in a gene-disruptant.

Abstract: According to one embodiment, a movable apparatus includes a carriage, coaxial paired wheels configured to support the carriage, a wheel actuator configured to rotationally drive the paired wheels, a loading section provided above the carriage, a swinging section includes a first swinging mechanism configured to swing the loading section around a first shaft extending in a direction crossing an axle of the wheels and a second swinging mechanism configured to swing the loading section around a second shaft provided parallel to the axle, acceleration sensing device configured to measure accelerations, and a swing angle control device configured to control the swing angle of each of the first swinging mechanism and the second swinging mechanism, to swing the loading section in a direction in which a component force of the acceleration applied to the loading section in a horizontal direction and a component force of gravity are balanced.

Abstract: A process for producing a lysosomal enzyme having a mannose-6-phosphate-containing acidic sugar chain, wherein the process comprising: culturing in a medium yeast cells obtained by introducing a lysosomal enzyme gene into a sugar chain biosynthetic enzyme gene mutant strain of yeast, collecting a lysosomal enzyme having a phosphate-containing sugar chain from the culture, and then treating the enzyme with ?-mannosidase; and pharmaceutical compositions for treatment of human lysosomal enzyme deficiencies produced by the process. The genetic engineering technique using the yeast according to the present invention allows large-amount and high-purity production of a glycoprotein having a phosphate-containing acidic sugar chain which can serve as a labeling marker for transporting into lysosomes in cells of mammals such as human. The glycoprotein having a phosphate-containing acidic sugar chain according to the invention may be utilized as a drug effective in treatment of human lysosomal enzyme deficiencies, etc.

Abstract: This invention provides a means for enabling high-level secretory production of proteins, in particular proteins having complicated structures such as antibodies, in host cells such as yeast cells. The invention also provides transformed yeast cells having the activated HAC1 gene and the RRBP1 gene and a method for enabling high-level secretory production of foreign proteins using such transformed host cells by inhibiting O-sugar chain formation indigenous to host cells such as yeast cells.

Abstract: The present invention relates to a means for generating a mucin-type glycopeptide or glycoprotein on a large scale in yeast. Specifically, the invention relates to a method which comprises introducing into a yeast at least one selected from the group consisting of a gene encoding UDP-GalNAc synthetase, a gene encoding UDP-GalNAc transporter, and a gene encoding polypeptide:O-GalNAc transferase, and, if desired, a gene encoding a mucin-type glycopeptide; and producing a mucin-type glycoprotein having O-GalNAc by use of the yeast.